1-Perfluorohexyloctane Ophthalmic Composition for Ocular Dryness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease, particularly those associated with Meibomian gland dysfunction, are inefficient and can be harmful due to the use of preservatives, and existing compositions do not effectively address ocular surface damage and symptoms of dryness.
Innovation Solution
A composition comprising 1-perfluorohexyloctane, optionally with 2-perfluorohexyloctane, is administered as a single drop up to four times a day to treat ocular surface damage and symptoms of dryness by reducing the ocular surface damage and alleviating symptoms such as dryness, burning, and blurred vision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If preservatives are used in ophthalmic formulations to maintain product stability and prevent contamination, then product reliability is improved, but ocular surface damage and symptoms of dryness worsen
Solution Approach 1:
The patent removes preservatives from the ophthalmic formulation entirely, extracting the harmful component while maintaining product effectiveness through alternative means (perfluorinated alkane-based lubricant composition that provides stability and contamination prevention without requiring preservative additives)
Solution Approach 2:
The patent converts the potential harm of preservative-free formulation (which might compromise product stability) into a benefit by using perfluorinated alkanes that inherently provide stability and contamination prevention mechanisms without requiring harmful preservative additives, thus eliminating the harmful effect while maintaining reliability
2Ease of operation
If artificial tears are used as lubricants to treat dry eye disease, then symptoms of dryness are improved, but ocular surface damage and discomfort worsen due to preservative content
Solution Approach 1:
The patent extracts and removes preservatives from the artificial tear formulation, providing symptom relief through a preservative-free perfluorinated alkane-based lubricant that eliminates the harmful component while maintaining therapeutic effectiveness for dry eye disease symptoms
3Productivity
If frequent use of preserved topical medicaments is made to manage moderate to severe dry eye disease, then symptom control is improved, but cumulative ocular surface damage worsens
Solution Approach 1:
The patent removes preservatives from the formulation, enabling frequent use (up to 4 times daily) without cumulative ocular surface damage, as the perfluorinated alkane-based lubricant provides effective symptom control without the harmful preservative components that would cause damage with repeated application
Data Source
AI summary
The present disclosure provides methods of treatment using ophthalmic compositions, comprising 1-perfluorohexyloctane, which are useful in the treatment of ocular surface damage of the cornea and/or symptoms of dryness.